TipRanks
Go Ultimate55% OFF

Clinica Baviera (D9Z) Stock Price & Analysis

D9Z Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 795.23M
Enterprise Value
CHF 882.45M
Total Cash (Recent Filing)
CHF 51.59M
Total Debt (Recent Filing)
CHF 9.90M
Price to Earnings (P/E)
19.1
Beta
0.39
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
2.41%

Bulls Say, Bears Say

Bulls Say

Steady Revenue Growth

Sustained revenue expansion indicates continuing demand for Clinica Baviera’s ophthalmology services and growing clinic activity. If maintained, this provides a durable foundation for operating leverage, broader market reach, and continued investment in clinical capacity and patient acquisition.

Strong Profitability

Consistently strong profitability suggests the clinic network is converting revenue into earnings efficiently across its ophthalmology services. Durable margins can support internal funding for expansion, provide resilience against moderate cost pressure, and strengthen the company’s ability to compete over the next several quarters.

Healthy Cash Generation

Operating cash flow consistently exceeding reported earnings supports the quality of Clinica Baviera’s profits and reduces reliance on external financing. Positive and improving free cash flow gives the company greater flexibility to fund reinvestment, maintain clinics, and pursue growth while preserving financial resilience.

Bears Say

Margin Volatility

Recent margin volatility creates uncertainty about how much of the company’s revenue growth will translate into lasting earnings growth. If the movement reflects changes in service mix, pricing, or costs, sustained pressure could limit operating leverage and reduce the profitability benefit of future clinic expansion.

Moderate Free-Cash-Flow Conversion

Although cash generation is positive, only moderate conversion of net income into free cash flow indicates that reinvestment requirements or working-capital movements absorb a meaningful portion of profits. This may constrain cash available for expansion, shareholder returns, or balance-sheet strengthening if it persists.

Deleveraging Durability Unclear

The recent reduction in leverage improves financial flexibility, but the contrast with historically higher debt-to-equity levels makes its durability an important consideration. If the improvement reflects timing rather than a structural change, future financing needs could again increase balance-sheet risk and restrict capital allocation.

Clinica Baviera News

D9Z FAQ

What is Clinica Baviera’s market cap?
Clinica Baviera’s market cap is CHF795.23M.
When is Clinica Baviera’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Clinica Baviera’s earnings last quarter?
Clinica Baviera released its earnings results on Jul 29, 2026. The company reported $0.685 earnings per share for the quarter.
Is Clinica Baviera overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Clinica Baviera pay dividends?
Clinica Baviera does not currently pay dividends.
What is Clinica Baviera’s EPS estimate?
Clinica Baviera’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinica Baviera have?
Clinica Baviera has 16,307,580 shares outstanding.
What happened to Clinica Baviera’s price movement after its last earnings report?
Clinica Baviera reported an EPS of $0.685 in its last earnings report. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Clinica Baviera?
Currently, no hedge funds are holding shares in CH:D9Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology